Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13045-016-0313-y http://scihub22266oqcxt.onion/10.1186/s13045-016-0313-y C5010774!5010774 !27590878     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27590878 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Hematol+Oncol 2016 ; 9 (1 ): 80 Nephropedia Template TP {{tp|p=27590878 |t=2016. Second-generation inhibitors of Bruton tyrosine kinase |pdf=|usr=}}{{27590878 }} gab.com Text Second-generation inhibitors of Bruton tyrosine kinase JO: J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27590878 #FOAvip Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111. Twit Text FOAVip Second-generation inhibitors of Bruton tyrosine kinase ????J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27590878 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27590878 #FOAvip English Wikipedia <ref>{{Cite pmid|27590878 }}</ref> Second-generation inhibitors of Bruton tyrosine kinase #MMPMID27590878 Wu J ; Liu C ; Tsui ST ; Liu D J Hematol Oncol 2016[Sep]; 9 (1 ): 80 PMID27590878 show ga Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111. |Adenine/analogs & derivatives [MESH] |Agammaglobulinaemia Tyrosine Kinase [MESH] |Benzamides [MESH] |Drug Resistance, Neoplasm/genetics [MESH] |Humans [MESH] |Imidazoles [MESH] |Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy [MESH] |Piperidines [MESH] |Protein Kinase Inhibitors/*therapeutic use [MESH] |Protein-Tyrosine Kinases/*antagonists & inhibitors/genetics/physiology [MESH] |Pyrazines [MESH] |Pyrazoles [MESH]Second-generation inhibitors of Bruton tyrosine kinase (epmc).pdf DeepDyve Pubget Overpricing